biostudies-literatureUnknown14(12)Wen X<h4>Background</h4>Accurate assessment of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for mitigating chemotherapy-related toxicity in patients who do not respond to the treatment. Conventional ultrasound (US) has become a pivotal method for evaluating treatment response due to its cost-effectiveness, convenience, and absence of ionizing radiation. The objective of this study was to develop a model combining US and clinicopathological characteristics at baseline, as well as US features after one cycle of NAC, to predict the pCR to NAC in BC.<h4>Methods</h4>This retrospective study included 74 patients with invasive BC who underwent NAC from January 2022 to December 2023. Data from US and clinicopathological characteristics before NQuantitative imaging in medicine and surgery8840-8851https://www.ebi.ac.uk/biostudies/studies/S-EPMC11652014biostudies-literatureModel based on ultrasound and clinicopathological characteristics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer.PMC11652014Deng BWen XChen JLin YSu ZZhong JZhuang YfalseModel based on ultrasound and clinicopathological characteristics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer.<h4>Background</h4>Accurate assessment of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for mitigating chemotherapy-related toxicity in patients who do not respond to the treatment. Conventional ultrasound (US) has become a pivotal method for evaluating treatment response due to its cost-effectiveness, convenience, and absence of ionizing radiation. The objective of this study was to develop a model combining US and clinicopathological characteristics at baseline, as well as US features after one cycle of NAC, to predict the pCR to NAC in BC.<h4>Methods</h4>This retrospective study included 74 patients with invasive BC who underwent NAC from January 2022 to December 2023. Data from US and clinicopathological characteristics before N2024-01-01T00:00:00Z2024 Dec2025-04-03T23:08:49.446Z2025-04-03T23:08:49.446ZS-EPMC116520143969871310.21037/qims-24-1268